NCT00421551View on ClinicalTrials.gov

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

February 28, 2011

Conditions
HIV Infections
Interventions
DRUG

Darunavir

during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day

DRUG

ritonavir

during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day

Trial Locations (1)

75013

Service des maladies infectieuses et tropicales Hopital Pitie salpetriere, Paris

All Listed Sponsors
collaborator

Tibotec Pharmaceutical Limited

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00421551 - Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 | Biotech Hunter | Biotech Hunter